Vitaran Eyes: Vitaran i or Vitaran PN? How to Choose the Right Box

The direct answer: choose the blue Vitaran i box when the planned treatment is for the delicate eye area, and choose the red Vitaran PN box when the plan is broader facial skin-quality treatment. On the two current MJS listings, both products contain sodium polynucleotide at 20 mg/mL (2% PN) and both are supplied as two 1 mL prefilled syringes. Concentration and pack volume therefore do not tell these two boxes apart.

The practical difference is the product identity and intended zone. Vitaran i is the thinner, eye-area member of the range; the standard HP Vitaran product is positioned for the face and larger skin areas. Neither is a structural filler, and neither should be chosen simply because one colour looks stronger or because a seller calls both products “Vitaran Eyes.”

The buying rule in one line: blue is the eye-area SKU; red is the facial SKU. Check the exact product name, carton colour, batch, expiry and enclosed instructions—not just the shared “PN 2%” claim.

Start with the box: blue Vitaran i versus red Vitaran PN

The two MJS products are easy to confuse because their names, active ingredient and pack size are almost identical. The current product photos provide the clearest first check: Vitaran i PN 1ml×2 is blue/aqua, while Vitaran PN 1ml×2 is coral red.

This is why the product selection cannot be reduced to “I is weaker” or “PN contains more active.” On the current listings, the amount of PN per millilitre is the same. The meaningful distinction is how the named formulation is positioned within the product family and which area the qualified practitioner has assessed.

Is “Vitaran Eyes” the name printed on the blue box?

Not always. “Vitaran Eyes” is a common search and clinic-facing name for the eye-area option, but the current MJS listing and product photo read Vitaran i. Other markets use names such as HP CELL VITARAN i, VITARAN I or VITARAN Eyes. That variation is one reason a purchase order should contain the exact SKU name and pack presentation rather than the word “Vitaran” alone.

Why do some websites compare Vitaran I with Vitaran II instead?

There are at least two naming systems in circulation. Some UK market material describes Vitaran I as a 2 × 1 mL format for smaller or periocular areas and Vitaran II as a 2 × 2 mL format for larger areas. BR Pharm’s current family material also shows blue Vitaran i, red HP Vitaran and purple Vitaran S as distinct range members.

Those systems should not be blended into a new product identity. This article compares the two actual MJS listings shown above: blue Vitaran i and red Vitaran PN, both currently listed as 2 × 1 mL. If an older brochure, supplier quotation or local box shows a different count, the physical carton and the enclosed instructions for that batch take priority over a generic comparison chart.

Are both products really 2% PN?

Yes, according to the current listings and manufacturer information reviewed for this guide. BR Pharm’s HP Vitaran product page states sodium polynucleotide at 20 mg/mL and a pack of two 1 mL syringes. Current Vitaran i regional information also lists 20 mg/mL, and both MJS pages use the same concentration.

“2% PN” and “20 mg/mL PN” express the same concentration in different formats: 20 milligrams in each millilitre equals 2 grams per 100 millilitres. It does not mean that 2% of the treatment result is guaranteed, and it does not establish that two different PN gels will behave identically in tissue.

What is PN, and why might it affect skin quality?

Polynucleotides are purified chains of nucleotides derived from fish DNA. In Vitaran, the label describes the active as sodium polynucleotide. Calling the finished product a “salmon sperm injection” is attention-grabbing but imprecise; the useful facts are the purified PN material, its concentration, the formulation and the product’s intended purpose.

The current scientific explanation has three relevant parts:

1. Water binding and the extracellular environment. PN is hydrophilic and can retain water within a gel-like matrix. This supports hydration and may improve the way dry, finely lined skin reflects light, but it does not create the projection expected from a structural filler.
2. Fibroblast and matrix signalling. Reviews describe PN and its breakdown products interacting with adenosine A2A receptor pathways and supporting fibroblast activity, extracellular-matrix organisation and tissue-repair processes.
3. The nucleotide salvage pathway. As PN is broken down, nucleotide components may be reused by cells through salvage pathways. This is a plausible biological explanation for gradual tissue support; it is not proof that a particular person will make a fixed amount of new collagen.

A recent review of PN and PDRN mechanisms discusses both A2A-receptor signalling and nucleotide salvage. A separate systematic review of injectable PN in aesthetic medicine found encouraging results across small studies but also substantial variation in products, methods and outcome measures. Mechanism and clinical evidence should therefore be read together, not turned into an unlimited “regeneration” promise.

Why can products with the same concentration have different roles?

Concentration tells you how much PN is present; it does not describe viscosity, spread, needle presentation or intended treatment area. The Vitaran family brochure distinguishes the blue eye-area product from the red facial product partly through their viscosity profiles. The blue formulation is positioned for thin, sensitive tissue around the eyes, while the red formulation is the core option for the entire face.

Think of concentration as only one line on the label. Two products can each contain 20 mg/mL PN and still be designed to handle differently. This is similar to two moisturisers containing the same percentage of one active ingredient but using different bases for different skin areas—except that an injectable medical device has much higher handling and safety stakes.

The difference does not establish that blue Vitaran i is universally safer around the eye or that red Vitaran PN is more powerful on the face. It means the professional should match the exact product format to the assessed area and follow that carton’s current instructions.

Which Vitaran should you choose for each concern?

Choose by anatomical problem and treatment goal, not by the word “rejuvenation.” Vitaran products are intended to support skin quality. They are not interchangeable solutions for every line, shadow, hollow or bag.

This distinction answers one of the most common social-media complaints: “I paid for under-eye PN, but my hollow is still there.” A hollow is a shape problem; crepey skin is a skin-quality problem. One person may have both, but changing the box colour does not make one treatment perform both jobs.

Can Vitaran i remove dark circles?

It may soften darkness that is partly caused by thin, poor-quality skin, but it cannot reliably remove every dark circle. Under-eye darkness can come from visible vessels, brown pigment, a tear-trough shadow, fat bulging, fluid retention, skin laxity or several of these at once. PN does not target all of them.

If the colour changes dramatically with lighting or improves when the skin is gently stretched, shadowing and anatomy may be important. If it remains brown in different lighting, pigment may play a larger role. This kind of cause-based assessment matters more than a generic claim that Vitaran “brightens eyes.”

What results are realistic, and when should they be assessed?

Expect a gradual change in texture, hydration, elasticity and fine-line appearance—not instant structural correction. The raised points and fullness visible immediately after treatment are part of the injection response. They are not the final result.

A small uncontrolled Vitaran I study of crow’s-feet used four treatments at two-week intervals and assessed participants through 18 weeks. It reported improvements in wrinkle measures, but the lack of a control group and the small sample mean the results should not be presented as a guaranteed percentage for every Vitaran customer.

Another randomized split-face study of 15 participants compared ionization-adjusted HP Vitaran I with Rejuran i around the eyes. Mean pain scores were lower with Vitaran I (3.39 versus 5.04 on a 10-point scale), while wrinkle-improvement measures were similar between products. That is useful product-specific comfort evidence, but it does not compare blue Vitaran i with red Vitaran PN and does not prove that every injection will be comfortable.

The broader category evidence is also modest. A randomized periocular PN-versus-non-cross-linked-HA trial included 27 participants and three sessions at two-week intervals. It found no significant difference in the overall visual improvement scores, although the PN-treated side performed better on some hydration, elasticity, roughness and pore measures. These findings support realistic skin-quality goals, not claims of permanent dark-circle or eye-bag removal.

What treatment course gives the best realistic result?

A short initial course with defined review points is more sensible than promising a result from one session or selling an open-ended package. Current regional Vitaran i guidance commonly describes three to four treatments, 15–30 days apart, followed by maintenance only if the initial course produced a worthwhile benefit. Direct Vitaran I studies have also used four treatments at two-week intervals.

Those schedules are close enough to define a useful planning range, but they are not identical. A practical framework is:

1. Before session one: identify whether the concern is eye-area skin quality, facial skin quality, pigment, hollowing, a fat bag or fluid. Take photographs in the same lighting, angle and expression.
2. Initial course: discuss three to four sessions roughly two to four weeks apart, using the exact product instructions and clinical assessment to set the final plan.
3. Before repeating: make sure the previous reaction has settled normally. Persistent swelling, inflammation or a new lump is a reason to reassess, not a reason to stay on the calendar.
4. Outcome review: review several weeks after the final session, when short-term swelling is no longer affecting the comparison. A later review around three months can show whether the change was durable enough to matter.
5. Maintenance decision: regional material sometimes suggests a maintenance session four to six months after the course. Treat that as a product-program reference, not a mandatory schedule for every patient.

The article deliberately does not provide injection points, depth, volume per point or technique. Those decisions depend on anatomy, the exact device, the local registration and the qualified practitioner.

Vitaran aftercare: what should you do after treatment?

The available Vitaran instructions give two useful time limits: avoid makeup for 12 hours, and avoid prolonged sunlight, UV exposure and extremes of heat or cold—including saunas and steam rooms—for two weeks. Check the leaflet supplied with the exact blue or red carton because versions can vary by market.

During the first 12 hours

Keep the treated area clean and leave the injection sites alone. Do not rub, press or massage them unless the treating professional has specifically instructed it. Avoid makeup, use clean hands near the face and keep skincare simple.

During the first few days

Allow raised points, redness and swelling to settle. Many clinics advise avoiding intense exercise, heavy alcohol, swimming and strong active skincare during the earliest recovery period because heat, friction and contamination can aggravate a freshly treated area. These are common-practice precautions; the clinic’s written instructions and the supplied IFU take priority.

Use gentle skincare and daily sun protection. Do not try to flatten a bump by pressing, puncturing it or adding another injectable. If the eye area looks more puffy than expected, contact the treating clinic rather than following a social-media massage routine.

For two weeks

Follow the IFU advice to avoid prolonged sun or UV exposure and extreme heat or cold. That includes saunas and steam rooms. Coordinate peels, lasers, microneedling and other injectables instead of stacking procedures simply because the surface looks settled.

Which reactions are expected, and which signs need urgent help?

Redness, swelling, itching, tenderness, small raised areas and bruising can occur after PN injection. The available Vitaran IFU states that inflammatory symptoms with itching or pain may last for about one week. It also lists possible nodular firmness, discolouration or little visible effect.

The key question is whether the reaction is improving. Contact the treating clinic promptly if inflammation continues beyond a week, if swelling repeatedly returns, if a lump or colour change persists, or if the area is becoming more painful instead of settling.

Seek urgent medical assessment for severe or rapidly escalating pain, pale or blanched skin, spreading mottled or dusky colour, cool skin, blistering, or any visual symptom such as blurred or lost vision, double vision, eye pain or a suddenly drooping eyelid. These are general warning signs of vascular or periocular injection emergencies, not common Vitaran effects. The IFU warns against intravascular placement because tissue necrosis can occur, and a multispecialty consensus on injection-related vision loss treats sudden visual change as an emergency.

Who may not be suitable for Vitaran?

Suitability depends on both the medical history and whether PN matches the actual concern. The available Vitaran instructions exclude or caution against use in pregnancy or breastfeeding, children and adolescents, active infection or inflammation at the site, known hypersensitivity to sodium polynucleotide, certain allergic, autoimmune or granulomatous diseases, recent filler treatment in the area and non-absorbable filler at the site.

The instructions also list NSAIDs, antiplatelet medicines, anticoagulants and immunosuppressants. This is a screening issue, not an instruction to stop prescribed medication. Never discontinue a medicine in order to qualify for an elective treatment; the prescriber and treating clinician must decide whether and when treatment is appropriate.

Because the material is fish-derived, disclose any fish or salmon allergy even if the exact wording differs between local leaflets. People with unexplained eye symptoms, a history of prolonged lower-eyelid swelling, active skin disease or a main concern that is clearly structural need especially careful assessment before any eye-area injectable.

Regulatory status also varies. Korean manufacturer information, CE material or sale through an international distributor does not establish approval for every indication in the UK, EU, Australia, United States or another destination. Professional buyers must verify the current local status and permitted use.

How should a professional buyer verify the right Vitaran box?

Verify product identity before comparing price. If a quotation says only “Vitaran PN 2%,” it has not yet told you whether the shipment will contain the blue eye-area carton or the red facial carton.

Use this receiving checklist:

1. Match the full product name on the quotation, outer carton and syringe labels.
2. Confirm the intended colour and range member: blue Vitaran i for the eye-area SKU, red HP Vitaran for the facial SKU.
3. Confirm the labelled concentration: sodium polynucleotide 20 mg/mL.
4. Confirm the actual pack count and syringe volume on the received box; do not assume every country or older brochure uses the same presentation.
5. Cross-check the batch/lot and expiry information between the carton and each prefilled syringe.
6. Reject an opened, damaged or suspicious seal and do not use an expired product.
7. Confirm the storage statement. Current official information places unopened HP Vitaran at 1–30°C, protected from sunlight.
8. Keep the enclosed IFU for the exact batch and market, and verify local professional-use eligibility before the product reaches the treatment room.

Vitaran i and Vitaran PN specifications

MJS is a distributor and channel seller, not the manufacturer or a treatment provider. The product pages are useful for identifying the stocked format, but the label, enclosed documentation and local regulations remain the controlling checks.

Frequently asked questions

Is Vitaran i the same as Vitaran PN?

They belong to the same PN range and the current MJS versions share 20 mg/mL PN and a 2 × 1 mL pack, but they are not the same purchasing identity. Blue Vitaran i is positioned for the eye area; red Vitaran PN is the core facial / broader-area product.

Is Vitaran Eyes stronger than Vitaran PN?

Not by concentration. Both current MJS listings state 20 mg/mL (2% PN). The eye-area distinction relates to the named formulation and its role within the range, not a higher or lower PN percentage.

Which colour Vitaran is for under eyes?

The current eye-area product is the blue/aqua Vitaran i box. The red box is the standard Vitaran PN facial product. Always verify the printed name as well as the colour because packaging can change.

Can the red Vitaran PN be used under the eyes?

Do not treat the two boxes as interchangeable from a retail article. The range provides a dedicated blue eye-area option, and the exact product selection belongs to the qualified practitioner working from the local IFU and the person’s anatomy.

How many Vitaran sessions are usually planned?

Current regional guidance often describes three to four sessions about 15–30 days apart. Direct Vitaran I studies have used four sessions at two-week intervals. The final schedule should be adjusted to the exact product instructions, treatment area, recovery and response.

When should Vitaran results be judged?

Do not judge the result from early swelling. Texture and fine-line change is better assessed several weeks into or after a course, with consistent photographs. A later review around three months from the first session can help separate genuine change from day-to-day hydration and lighting.

Does Vitaran i fill tear troughs or remove eye bags?

No. It is a skin-quality product, not a structural filler or a treatment that removes protruding fat. It may improve the skin overlying a hollow or bag while the underlying shape remains.

Can Vitaran be injected at home?

No. These are professional injectable medical devices. The eye area has vascular and visual risks, and a prefilled syringe does not make self-injection safe.

What should be written on a purchase order?

Use the complete product name, intended carton, concentration and pack format—for example, “blue Vitaran i PN, 20 mg/mL, 2 × 1 mL” or “red Vitaran PN, 20 mg/mL, 2 × 1 mL.” Ask the supplier to confirm the actual batch presentation if local packaging differs.

The useful conclusion

The current blue and red MJS boxes contain the same declared PN concentration and the same total syringe format, so the choice is not about getting “more PN.” Blue Vitaran i is the eye-area option; red Vitaran PN is the facial and broader-area option. A good order starts with the treatment zone, then confirms the exact carton name, batch, expiry, seal, storage and local documentation.

For treatment expectations, keep the goal equally precise. PN can reasonably be discussed for gradual skin-quality change—hydration, texture, elasticity and fine-line appearance. It should not be sold as an instant filler, a guaranteed dark-circle remover or a way to erase structural eye bags.

Evidence reviewed

1. MJS: Vitaran i PN 1ml×2 and MJS: Vitaran PN 1ml×2 — current stocked names, product photographs, concentration, presentation and eye-versus-face positioning.
2. BR Pharm: HP Vitaran — manufacturer composition, 2 × 1 mL packaging, intended purpose, storage and manufacturer identity.
3. BR Pharm Vitaran family brochure — blue Vitaran i, red HP Vitaran and purple S range roles, shared 20 mg/mL PN and relative viscosity/area positioning.
4. Vitaran instructions for use — contraindications, reactions, aftercare, packaging checks and storage. The linked document is a 2021 regional version; the leaflet supplied with the exact carton takes priority.
5. Vitaran i regional product information — current 20 mg/mL, 2 × 1 mL eye-area listing and common three-to-four-session programme.
6. Vitaran I crow’s-feet study — product-specific concentration, course and follow-up; small uncontrolled design limits generalisation.
7. Vitaran I versus Rejuran i pain study — randomized split-face study of 15 participants; lower mean pain score with Vitaran I and similar wrinkle-improvement measures.
8. PN versus non-cross-linked HA periocular trial — 27-person randomized split-face trial and measured skin-quality outcomes.
9. Systematic review of PN in aesthetic medicine and PN/PDRN mechanism review — overall evidence limits and proposed A2A/salvage-pathway mechanisms.
10. Consensus on injection-related vision loss — general periocular emergency recognition; not a Vitaran-specific incidence estimate.

Evidence last reviewed 9 September 2026. Product names, packaging and regulatory status can differ by market and batch. Verify the current physical carton, enclosed instructions and destination-market rules before professional use or purchase.